Vidyasagar D, Shimada S
Department of Pediatrics, University of Illinois Hospital Medical Center, Chicago.
Clin Perinatol. 1987 Dec;14(4):991-1015.
Exogenous surfactant therapy in infants with HMD leads to dramatic improvement in oxygenation and disease course. Both prophylactic and rescue treatments have shown a significant reduction in morbidity and mortality from the disease. There are several questions yet to be answered regarding the most effective surfactant, the appropriate time of treatment, and the appropriate dose, as well as the number of treatments required. Based on the available data, surfactant TA has shown promising and consistent results. Another important question to be answered is the role of surfactant in milder cases of HMD and its impact on the cost of hospitalization. Hopefully, future studies will be able to provide answers to these questions.
对患有新生儿呼吸窘迫综合征（HMD）的婴儿进行外源性表面活性剂治疗可显著改善氧合及病程。预防性治疗和挽救性治疗均已显示可显著降低该疾病的发病率和死亡率。关于最有效的表面活性剂、合适的治疗时间、合适的剂量以及所需的治疗次数，仍有几个问题有待解答。根据现有数据，表面活性剂TA已显示出有前景且一致的结果。另一个有待解答的重要问题是表面活性剂在病情较轻的HMD病例中的作用及其对住院费用的影响。有望未来的研究能够回答这些问题。
